"We assessed 140 patients with CDI episodes, 70 patients treated with fidaxomicin and 70 with vancomycin. at a hospital from January 2019 to March 2022. Fidaxomicin group had more recurrent CDI episodes within six months (59% vs 11%, p ≤ 0.001), more severity (43% vs 16%, p ≤ 0.001) and less treatme